Gynecologic cancer patients who had not been received paclitaxel therapy. Hypersensitivity reaction Paclitaxel hypersensitivity reaction anaphylaxis Premedication Hydrocortisone Dexamethasone
Conditions
Interventions
the nurses will record and report to doctor for management that following NCCN guideline.
,1.Hydrocortisone 100 mg,
dexamethasone 20 mg,
the nurses will record and report to doctor for management that following NCCN guideline.
Active Comparator Drug,Active Comparator Drug
Dexamethasone 20 mg intravenous,hydrocortisone 100 mg and dexamethasone intravenous
1. Dexamethasone 20 mg,
Ranitidine 50 mg,
Chlorpheniramine 10 mg intravenous 30 minutes before paclitaxel administration
and other premedication including diphenhydramine 25 mg 2 capsule orally and Ondransetron 8 mg intravenously.
2. Patient
induced hypersensitivity reactions,
Oncology nursing forum.
4.If hypersensitivity reaction had occured,
Sponsors
none
Eligibility
Sex/Gender
Female
Age
25 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Gynecologic cancer patient who had pathology report 2.Need paclitaxel therapy 3.Patient who had not been received paclitaxel 4.Bone marrow, kidney,and liver were with in normal limit
Exclusion criteria
Exclusion criteria: 1.allergy to hydrocortisone 2.patient who had been received paclitaxel 3.patient who had history of paclitaxel allergy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of hypersensitivity reaction during intravenous paclitaxel infusion medical record about hypersensitivity reaction during intravenous paclitaxel infusion | — |
Secondary
| Measure | Time frame |
|---|---|
| none none none | — |
Countries
Thailand
Contacts
Public ContactDhammapoj Jeerakornpassawat
Obstetrics and Gynaecology Department, Faculty of Medicine, Chiang Mai University
Outcome results
None listed